Buprenorphine is used as a sublingual medication in the treatment of opioid dependence. However, its misuse by i.v. injection may limit its acceptability and dissemination. A buprenorphine/naloxone (ratio 4:1) combination has been developed to reduce diversion and abuse. So far, the relevance of this combination has not been investigated in the animal models traditionally used to study the reinforcing effects of drugs of abuse. The aim of this study was to compare the rewarding effects, assessed by conditioned place preference (CPP), of buprenorphine and buprenorphine/naloxone combination following i.v. administration in mice. Animals were treated with different doses of buprenorphine or buprenorphine/naloxone combination (ratio 4:1), and CPP conditioning trial duration was 5 or 30 min. At the longest trial duration, a bell-shaped dose-response curve was obtained with buprenorphine, which was shifted significantly to the right with naloxone combination. At the shortest trial duration, an aversive effect was observed with the buprenorphine/naloxone combination in animals, involving opioid receptor-like 1 (ORL1). These findings may explain the discrepancies reported in the literature as some authors have shown a reduced buprenorphine/naloxone misuse compared to buprenorphine in opioid abusers, while others have not.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S146114571400025X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission.
West J Emerg Med
November 2024
Department of Emergency Medicine, University of Texas Medical Branch, Galveston, Texas.
Article Synopsis
- The study focuses on assessing the impact of buprenorphine-naloxone on mortality and remission rates among patients with opioid use disorder (OUD), amidst rising opioid-related deaths in the U.S.
- Using data from nearly 92 million medical records, the research compares outcomes between patients treated with buprenorphine-naloxone and a control group not receiving this treatment.
- Findings indicate that patients on buprenorphine-naloxone experienced 34% fewer deaths and approximately 1.9 times higher remission rates compared to those who did not receive the medication.
Adding naloxone to buprenorphine during pregnancy was not linked to increased adverse neonatal or maternal outcomes.
Ann Intern Med
December 2024
Mayo Clinic, Rochester, Minnesota, USA (B.S.).
Article Synopsis
- The study published in JAMA investigates the relationship between maternal use of certain medications during pregnancy and the risk of adverse outcomes for both mothers and infants.
- It analyzes data from a large cohort to identify any potential risks linked to these medications, aiming to provide clearer guidelines for safe prescribing during pregnancy.
- The findings highlight the importance of informed decision-making for healthcare providers and expectant mothers to minimize health risks associated with medication use in pregnancy.
Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.
Addict Sci Clin Pract
November 2024
Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA.
Background: Opioid use disorder (OUD) remains a significant public health issue as the number of opioid-related overdose deaths continues to reach new highs each year. Buprenorphine/Naloxone is a medication that has been shown to be highly effective for the treatment of OUD. However, the clinical management of patients on this medication is challenging as many patients discontinue treatment prematurely.
View Article and Find Full Text PDFDRAMES and DTA databases: Complementary tools to monitor drug-related deaths in France.
Therapie
October 2024
Addictovigilance Dept, Grenoble-Alpes University Hospital, 38000 Grenoble, France.
Introduction: The DRAMES (décès en relation avec l'abus de médicaments et de substances) registry is a French database of drug-related deaths (medications or illicit drugs) among drug users. The DTA (décès toxiques par antalgiques) registry is a French database of analgesic-related deaths among people without a history of drug abuse. Both registries are based on the collection of data on deaths for which forensic toxicology experts have performed analyses.
View Article and Find Full Text PDFContinuation versus Interruption of Buprenorphine/Naloxone in Adult Veterans Undergoing Surgery: Examination of Postoperative Pain and Opioid Utilization in a National Retrospective Cohort Study.
Anesthesiology
February 2025
Department of Anesthesiology, Roswell Park Cancer Institute, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.
Background: Prescription rates for buprenorphine in opioid use disorder are increasing, and recent guidelines recommend its continuation during and after surgery; however, evidence from clinical outcome studies is limited. The authors tested the hypotheses (1) that perioperative continuation of buprenorphine does not result in higher pain scores and (2) that this approach does not result in higher supplemental postoperative opioid requirements.
Methods: The Veterans Affairs Corporate Data Warehouse was queried for patients who underwent surgery while being prescribed buprenorphine/naloxone for opioid use disorder between 2010 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!